In this interview, CFO Michael Hunt explains the core technology of ReNeuron’s business, the stem cell science it is developing, optimising and harnessing to create therapeutic products. He discusses the recently reported early Phase II clinical trial data for its CTX stem cell therapy in stroke and why this has given ReNeuron the confidence to commence a pivotal Phase II/III clinical trial in 2017. Finally, he also discusses expected newsflow resulting from the remainder of ReNeuron’s pipeline – critical limb ischaemia (Phase I) and hRPC or retinitis pigmentosa (Phase I/II).